A Phase 2 Study Of PF-00232798 In HIV Positive Patients

• Drug: PF-00232798
  
  Solution, 20 mg. once daily, 10 days
• Drug: PF-00232798
  
  Solution, 150 mg. once daily, 10 days
• Drug: PF-00232798
  
  Solution, 5 mg. once daily, 10 days
• Drug: PF-00232798
  
  Solution, 40 mg. once daily, 10 days
• Drug: PF-00232798
  
  Solution, 300 mg. once daily, 10 days
• Drug: PF-00232798
  
  Solution, 400 mg. once daily, 10 days

• Active Comparator: PF-00232798 40 mg
  
  Intervention: Drug: PF-00232798
• Active Comparator: PF-00232798 300 mg
  
  Intervention: Drug: PF-00232798
• Active Comparator: PF-00232798 400 mg
  
  Intervention: Drug: PF-00232798
• Active Comparator: PF-00232798 5 mg
  
  Intervention: Drug: PF-00232798
• Active Comparator: PF-00232798 20 mg
  
  Intervention: Drug: PF-00232798
• Active Comparator: PF-00232798 150 mg
  
  Intervention: Drug: PF-00232798

Inclusion Criteria:

• Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
• Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.

Exclusion Criteria:

• Patients who have received any experimental drug within the past four months (prior to the first dosing day of the study) or who have previously received another CCR5 antagonist.
• Patients with evidence of decompensated liver disease.